HER2-positive breast cancer is marked by the overexpression of a specific receptor that accelerates cell growth, leading to the use of pertuzumab in its treatment. This monoclonal antibody, combined with trastuzumab and chemotherapy, offers an effective dual blockade approach. With FDA backing based on the APHINITY trial, pertuzumab has demonstrated significant clinical benefits, especially in […]
3 minute read
HER2 positive breast cancer, recognized for its accelerated growth due to protein overproduction, represents a significant subset of breast cancer diagnoses. Identifying HER2 status is critical, as it shapes treatment paths utilizing specialized therapies like Trastuzumab and combination methods. The challenge of resistance and side effects requires ongoing innovation and patient support. Staying informed about […]
3 minute read
Kisqali (ribociclib) emerges as a pivotal medication in treating hormone receptor-positive, HER2-negative breast cancer, offering enhanced therapeutic outcomes, particularly in combination with hormone therapies. Unveiling its mechanism of action, side effects, and pre-treatment considerations, this article elucidates the essential aspects of Kisqali therapy, emphasizing informed decision-making. From dietary restrictions to lifestyle adjustments, explore how these […]
3 minute read